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Introduction 
 
New psychoactive substances (NPS) have risen to prominence in recent years, and 
stakeholders across Scotland have raised concerns about the impact of these 
substances on individuals, services and local communities.  Much, though, is still 
unknown about the scale and associated harms of NPS-use in Scotland.  While 
there is increased awareness of the issue across sectors, work is needed to 
strengthen the evidence base on NPS.  This is crucial to ensuring an effective and 
proportionate response to the problem.   
 
The report considers the state of knowledge on NPS in Scotland, with a focus on 
prevalence and harm.  As part of this, proposals are made which may inform future 
work, closing evidence gaps on NPS. 
 
 
Main Findings 
 
A diverse market: Within the broad category of NPS, there is diversity in substance 
types.  These are being utilised by different subgroups of the population, for different 
reasons and in different ways and settings. 
 
NPS present in Scotland: Police Scotland’s ‘day of action on NPS’ identified 37 
different chemical compounds present across hundreds of NPS products.  The 
majority of these were synthetic cannabinoids.  However, due to the nature of the 
NPS market, other forms of NPS may quickly become available in Scotland.   
 
Access to NPS: Although ‘head-shops’ and online stores are important points of 
access to NPS for users, similarly to established drugs, NPS are often obtained 
through peer groups.  Street-level dealers have also moved into the NPS market.  
Primary points of access to NPS are likely to vary by user group. 
 
Motivations for NPS-use: The main motives for NPS-use include greater availability 
and lower price than established drugs, legality and a preference for the effects of 
particular forms of NPS.  Again, the constellation of key motivations for NPS-use will 
vary by user group. 
 
Prevalence of NPS-use: Data from the Scottish Crime and Justice Survey (SCJS) 
suggests that prevalence of NPS-use in the general population and in comparison to 
established drugs is low.  There are, though, limitations to this data.  Prevalence of 
NPS-use within subgroups of the general population, including marginal groups such 
as chaotic drug users and individuals with mental health issues, is missed.  The 
scale of use may be significantly higher in some subpopulations. 
 
Harms associated with NPS-use: Issues in responding to the emergence of new 
forms of NPS, identifying chemical compounds present in NPS products and gaps in 
reporting mean that comprehensive evidence on the harms of NPS is limited.  
Certain patterns of use may place users at greater risk, for example, polydrug use 
and/or injecting NPS.   
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Defining NPS 
 
The Home Office recently defined NPS as ‘psychoactive drugs, newly available in 
the UK, which are not prohibited by the UN Drug Conventions, but which may pose a 
public health threat comparable to that posed by substances listed in these 
conventions’.1  This wide definition has some utility in mapping out the boundaries of 
the issue.  For example, it notes that such drugs are not new per se, but ‘newly 
available’.  The EMCDDA adds that ‘this is an area characterised by limited data on 
use, with the risks and harms largely unknown, and where high potency levels are of 
serious concern’.2 
 
Stakeholders in Scotland, though, have noted a degree of uncertainty at ground level 
over what does and does not constitute an NPS.  This has implications both for 
gathering and sharing data on the issue.  For example, during the Scottish 
Government Evidence Group Meeting on NPS on 26 August 2014, it was questioned 
whether a substance such as mephedrone, which has been under control in the UK 
for over 4 years and is relatively well-understood, should still be referred to as an 
NPS.  Further to this, inconsistency in terminology was raised: when the term ‘legal 
high’ may be used and whether NPS refers to the chemical compound(s) or ‘brand 
name’.3  This ambiguity also extends to the categorisation of different forms of NPS.  
For example, NPS may be placed under their chemical compound group (e.g. 
synthetic cannabinoid, cathinone, piperazine, etc.) or according to their 
neurochemical effect (e.g. stimulant, sedative, dissociative, hallucinogenic, etc.).   
 
These questions may be resolved through consultation with key organisations and 
the rolling-out of practical, Scottish national guidelines for defining and categorising 
NPS.  A clear and settled schema, establishing standardisation across sectors, 
would ease communication between stakeholders and the collection of data on the 
issue.4 
 
This would also help to ensure distinctions are made between different forms of 
NPS.  The umbrella term ‘NPS’, and the common challenges of substances in this 
area, must not obfuscate the distinct demographics and patterns of use between 
different forms of NPS.  For example, reports suggest that NPS are used as 
substitutes for established drugs.  Club drug users, then, may seek out empathogen 
and stimulant-type NPS, while heroin users look to opioid and ‘downer’ NPS.  
Additionally, a first-time drug user may favour a synthetic cannabinoid over cannabis, 
but then never move onto other forms of NPS.  Within the broad category of NPS, 
then, there is variety in substance-types, and these are being utilised by different 
groups, in different settings, for different reasons.  Drawing out these distinctions is 
crucial to understanding prevalence of NPS-use within subpopulations and matching 
particular NPS to acute and long-term harms.  This includes the relationship between 
                                            
1
 Home Office, (2014), New Psychoactive Substances Review: Report of the Expert Panel, p.4. 
2
 EMCDDA, (2014a), Perspectives on Drugs: Synthetic Cannabinoids in Europe, p. 2 
3
 The EMCDDA, for example, suggests that a distinction be made between NPS, which refers to the 
chemical compound, and ‘legal high’ – the product sold openly, under a brand name via the internet 
and ‘head-shops’.   
4
 The UK Drug Watch Drugs Wheel provides a useful model for categorising NPS, placing them 
according to their neurochemical effect and showing their relationship to established drugs 
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the consumption of established drugs and NPS.  A national-level model for 
identifying and categorising NPS should recognise this nuance. 
 
 
Proposal  
 
Work with stakeholders to formulate national guidelines for defining and categorising 
NPS.  By establishing standardisation across organisations, the collection and 
sharing of data will be enhanced.  This is crucial to strengthening the evidence base 
on NPS. 
 
 
 
The NPS market in Scotland 
 
Production and supply of NPS 
 
NPS are designed to circumvent existing drug laws.5  They typically mimic controlled 
drugs, such as cannabis, cocaine and MDMA, but are chemically distinct from these 
substances.  Many NPS were synthesized as far back as the 1970s, and have 
recently been ‘rediscovered’ and reintroduced to the drug market.6  These and other 
forms of NPS may be modified, altering their chemical structure to stay ahead of 
drug controls.7  Moves to place NPS under control, then, often have the unintended 
consequence of fuelling innovation in the market.   
 
Producers in China and India are believed to be the main suppliers of NPS to the 
European market, although local producers have also been identified.8  These 
suppliers are linked both directly and indirectly through European networks, to 
distributors in Scotland and the rest of the UK.  NPS may be imported as packaged, 
branded products, or wholesale chemicals, which are then mixed with other 
substances and sold under different names.  This adds to uncertainty over the 
chemical contents of NPS products.  Elements of organised crime are believed to be 
involved in the NPS trade, but this does not currently constitute their primary 
commodity.  Police Scotland continues to work with UK and EU partners in law 
enforcement to map supply in NPS source and transit countries. 
 
 
                                            
5
 There are exceptions to this.  Khat, for example, is widely used in the Horn of Africa and the Arabian 
Peninsula as a mild stimulant.  The market for this drug has been based around migrant communities 
from these areas settling in the UK.  
6
 UNODC, (2013), The Challenge of New Psychoactive Substances, a Report from the Global 
SMART Programme, UNODC: Vienna, p.1. 
7
 The EMCDDA describes how chemists are accessing ‘the back catalogue of chemical substances 
developed by the pharmaceutical and medical research industries’, and exploiting access to cheap 
chemicals to synthesise such substances in bulk.  EMCDDA-Europol, (2014), EMCDDA-Europol 
Annual Report on the Implementation of Council Decision 2005,  p.6. 
8
 Production of NPS was also identified in Scotland.  The operation involved export of a particular 
NPS to Australia, where it had been banned. (DCI Garry Mitchell, interview with the Author, 2 October 
2014) 
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Case Study One: Synthetic Cannabinoids9 
 
Synthetic cannabinoids act on the same receptors in the brain as cannabis.  There is 
extensive variation in the chemical structure of NPS in this group.  The EMCDDA 
reported the identification of 102 new forms of synthetic cannabinoid between 2009 
and 2013, a number of which have since been placed under control in the UK.   
 
To replicate the user experience of cannabis, the cannabinoid is mixed with acetone 
(or an equivalent) and sprayed onto plant material.10  This ‘carries’ the chemical 
mixture and allows users to smoke the NPS.  As in the case of many other forms of 
NPS, there is limited evidence on the pharmacology and toxicology of this group of 
substances in humans.  In addition to this, there is extensive ‘inter-and intra-batch 
variability in ‘legal high’ products containing synthetic cannabinoids’, both in terms of 
contents and potency. 
 
 
Access to NPS 
 
High-street ‘head-shops’ and online stores are important sources of NPS for users.  
NPS, sold under brand names, such as ‘Gogaine’ and ‘Spice’, are marketed as 
‘research chemicals’, ‘bath salts’ or ‘herbal incense’, for example.  Packaging also 
carries warnings against human consumption.  In this way, sellers seek to evade 
trading standards and consumer protection controls, staying within the boundaries of 
the law.11  In the absence of bespoke legislation against the selling of NPS, Police 
Scotland has faced challenges in addressing the issue.   
 
It is difficult to establish how much of the demand for NPS in Scotland is met directly 
by ‘head-shops’ and online stores.  The experience of some stakeholders suggests 
that most NPS in Scotland are bought from street-level dealers.  The Scottish Crime 
and Justice Survey12 (SCJS) noted in 2012/13 that, of all those who had taken drugs 
in the last month, 1.8 per cent and 0.4 per cent reported accessing  their ‘most used 
drugs’ from a shop or online respectively.  It must be noted, though, that this 
represents a percentage of the total drug market and does not include more sporadic 
drug users.   
 
In addition to this, the 2013 Global Drug Survey (GDS)13 found that 53 per cent of 
UK respondents who had used NPS obtained it from the internet, 43 per cent from a 
shop, 18 per cent from a friend and 9 per cent from a dealer.14  It may be assumed 
                                            
9
 Drawn from EMCDDA, (2014a) Perspectives on Drugs: Synthetic Cannabinoids in Europe  
10
 For example, large quantities of damiana leaf have been seized in Scotland, reportedly for this 
purpose. 
11
 This also means that ‘head-shop’ operators will not offer advice on ‘safe’ consumption of the 
products they sell; doing so would leave them open to prosecution.  See Home Office, (2014), New 
Psychoactive Substances Review: Report of the Expert Panel, p.15. 
12
 Robertson, Laura, with Bates, Ellie, (2014), The Scottish Crime and Justice Survey Drug Use, 
Scottish Centre for Crime and Justice Research: University of Glasgow, Scottish Government Social 
Research 
13
 Mixmag (2013) Mixmag’s Global Drug Survey: The Results, accessed 3.2.2015  
14
 This survey comes with caveats around self-selection, e.g. the survey is targeted at clubbers, while 
marginal subpopulations are likely to be under-represented.   
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that a large proportion of NPS obtained from peer groups also originated from ‘head-
shops’ and online sources.  Furthermore, the 2014 GDS15 found that 20.5 per cent of 
all Scottish respondents had experience of purchasing drugs from the internet.16   
 
Although these trends would indicate a sizable number of users purchasing NPS 
from ‘head-shops’ and websites, it should be noted that the GDS is largely targeted 
at clubbers.  For other NPS-user subgroups, the picture may be different.  For 
example, long-term opiate users may be purchasing certain forms of NPS alongside 
heroin from street-level dealers.  Work is needed to map pathways to NPS-use for 
different sub-groups in Scotland. 
 
NPS present in Scotland 
 
The composition of supply and demand for NPS changes rapidly.  However, Police 
Scotland’s ‘day of action on NPS’ on 22 August 2014 gave a ‘snapshot’ of the 
market.17  Working with partner enforcement agencies, 6000 packets of NPS were 
recovered from 58 ‘head-shops' throughout the country.  Analysis of 400 samples 
identified 37 different chemical compounds present across samples, but with great 
variation in the contents of products, e.g. chemical mixture, potency and ratio.  This 
extended to packages carrying the same brand name.  The vast majority of these 
recovered packages contained no controlled substances.18  Reflecting trends at 
European-level, cannabinoids made up the largest share of recovered NPS 
products.  Additionally, Police Scotland seizure data indicates that mephedrone and 
ketamine, banned substances which may fall into the NPS bracket, remain on the 
market, although seizures of these drugs are considerably lower than for cannabis or 
cocaine. Figures from 2012/13 show that there were 21,169 seizures of cannabis, 
2,140 seizures of cocaine, 194 of mephedrone and 19 of ketamine19. 
 
In 2013, the UK Forensic Early Warning System (FEWS) reported 11 new forms of 
NPS to the EMCDDA20.  In the same year, the EMCDDA Early-Warning System 
(EWS) detected 81 new forms of NPS European-wide, which compares to 74 in 
2012, 49 in 2011 and 41 in 2010.21  While many of these NPS fail to become popular 
or are only available in a limited number of countries, the figures demonstrate the 
rate of change in the NPS market and the large number of NPS which may 
potentially become available in Scotland.  In addition to this, the internet enables 
NPS distributors to reach consumers across borders.  The EMCDDA identified 651 
online stores selling NPS across the EU in 2013.22  Online stores may offer NPS not 
present in Scottish ‘head-shops’, including substances which have been placed 
                                            
15
 Winstock, A (2014) The Global Drug Survey 2014 Findings, accessed 3.2.2015  
16
 This may also include ‘dark web’ purchases of established drugs, though. 
17
 Carried out as part of Police Scotland’s Operation Redwall. 
18
 Police Scotland’s findings correlate with the UK-wide picture: ‘Analysis of NPS samples collected by 
The UK Forensic Early Warning System (FEWS) (in 2013/14) found that around nine out of ten were 
mixtures of either two (61 per cent) or three (30 per cent) different active components. The analysis 
also found that few samples collected from the internet or 'head-shops' contained controlled drugs’. 
See Home Office, (2014), New Psychoactive Substances Review: Report of the Expert Panel, p.8. 
19
 Scottish Gov., (2014), Drug Seizures by Scottish Police Forces, 2012-13,  
20
 Home Office, (2014), New Psychoactive Substances Review: Report of the Expert Panel, p. 8 
21
 EMCDDA-Europol, (2014), EMCDDA-Europol Annual Report on the Implementation of Council 
Decision 2005, p.5. 
22
 Ibid. (It is unclear how many of these sites offer delivery to Scottish consumers) 
 7 
 
under control in the UK.  Monitoring the NPS market in Scotland, then, presents 
significant challenges. 
 
NPS and the illicit drug trade 
 
NPS are also present in the illicit drug trade in Scotland.  This has two main aspects.  
First, reports suggest that drug dealers have moved to meet demand for NPS which 
have been made illegal, e.g. mephedrone.  Placing substances under control, then, 
may also have the unintended consequence of pushing NPS into the illicit sphere.  
Second, unbeknown to users, NPS are used as adulterants and substitutes for 
established drugs by suppliers and dealers.   
 
Cheap forms of NPS are cut with drugs such as cocaine, to increase profit margins.  
This is intended to maintain potency, but users may experience unwanted and/or 
adverse reactions to the substance.  There may also be hidden acute and/or long-
term harms from mixing NPS with different drugs.   
 
Further to this, fake ecstasy pills, substituting MDMA for an NPS, pose substantial 
dangers.  NPS may offer a cheaper and/or more available alternative than MDMA for 
suppliers and dealers, while entailing greater health risks for consumers.23  The 
emergence of ‘Green Rolex’ pills in 2013 is an example of this phenomenon.  The 
pills were found to contain PMA (methoxyamphetamine), which is more toxic than 
MDMA, has a longer delay in effect and a steeper dose-response curve.  Users, 
believing that the pills had low MDMA content due to the delayed effect time of PMA, 
took additional doses, exposing themselves to higher toxicity and more intense 
effects.  Seven deaths in Scotland were linked to the pills before they faded from the 
market.  The Glasgow Drug Trend Monitoring Group played a pivotal role in 
formulating and sharing effective warning messages on the potential harms of these 
pills.  Such practices, though, are by their nature reactive, rather than proactive in 
reducing harm. 
 
In the Netherlands, widely available ‘pill-testing’ facilities are believed to be 
responsible for the withdrawal of fake ecstasy from the domestic market.  As users 
have become more aware of what they are consuming, suppliers have been forced 
to withdraw such products.  Additionally, harm reduction messages around 
consuming ecstasy are more effective, i.e. tailored to MDMA rather than an NPS with 
incomplete knowledge on the associated harms.  The provision of such facilities, 
though, may also have led to higher MDMA content in ecstasy pills sold to Dutch 
users, and the diversion of PMA ‘ecstasy’ to the UK market.24   
 
 
Proposal 
 
Support work mapping the market for NPS in Scotland, including how different 
subgroups are accessing NPS.   
 
Explore the possible advantages and disadvantages of introducing ‘pill-testing’ 
                                            
23
 EMCDDA, (2013), The EU Drug Markets Report: a Strategic Analysis, p.108. 
24
 Power, Mike, (2013), ‘Killer Pills: Myth or Murder?’, Mixmag,, 4 April 2013 . 
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facilities in Scotland as a harm-reduction measure. 
 
 
Motivations for NPS-use in Scotland  
 
Work is needed to establish the motivations for NPS-use in Scotland.  As discussed 
previously (page 2-3), there is diversity in the NPS market, which means that there is 
likely to be variation between user groups along this variable.  The general 
motivations for taking NPS are assumed to be similar to those for established drugs, 
e.g. peer pressure, boredom, etc.  The question, then, is what is distinct about 
demand for NPS?  Stakeholders in Scotland have identified common themes. 
 
 Availability and cost: NPS are generally more accessible than established 
drugs.  Buying from ‘head-shops’ or the internet cuts out the ‘middle-man’, i.e. 
drug dealers.  Additionally, some NPS are perceived to be of higher purity and 
lower cost than established drugs.  For example, the rise in demand for 
mephedrone in 2010 is correlated to falls in the purity of cocaine in the UK. 
 
 Legality: Users wary of being prosecuted for drug offences may favour ‘legal 
highs’.  Related to this, NPS are generally not picked-up on drug tests.  The 
legality of certain forms of NPS also carries connotations of safety for some 
users, who falsely assume these products carry fewer health risks than 
controlled drugs. 
 
 Preference for NPS effects: Users may favour the effects of certain NPS over 
established drugs.  For example, where mephedrone initially emerged as an 
alternative to cocaine, the drug is now popular in its own right.  There may 
also be a desire to experiment with new forms of NPS; chasing new and 
distinct experiences. 
 
Some of these motivations may be more important to different NPS-user groups than 
others.  For example, avoidance of detection in drug tests may be a primary motive 
for prisoners, while cost is an important consideration for teenage users.25  
Respondents to the 2012 GDS, which focuses on clubbers, rated the ability to buy 
online and the unavailability of other drugs as the most influential factors behind NPS 
use.26  Measham argues that understanding such motivations, and mapping the 
relationship both between them and with the illicit drug market, is key to identifying 
NPS-user groups.27 
 
 
Proposal 
Consider commissioning research into the motivations of NPS-use in key subgroups 
of the population, e.g. high school pupils, college/university students, long-term drug 
users, etc. 
 
                                            
25
 Home Office, (2014), New Psychoactive Substances Review: Report of the Expert Panel, p.13. 
26
 Mixmag, (2012), Mixmag’s Drug Survey: The Results, 14 March 2012 
27
 Measham, Fiona, (2013), ‘Social Issues in the Use of Novel Psychoactive Substances: 
Differentiated Demand and Ideological Supply’, in Dargan & Wood, (Eds.), Novel Psychoactive 
Substances: Classification, Pharmacology and Toxicology, London: Academic Press, pp.105–127. 
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Prevalence of NPS-use in Scotland 
 
Survey data 
 
Existing sources would suggest that the scale of NPS-use in Scotland is relatively 
small.  The SCJS gathers information on the prevalence of self-reported drug use 
among the general population, aged 16 and over28.  For 2012/13, 0.5 per cent of 
adults reported taking a ‘new drug’ in the last year.  The ‘new drugs’ included in the 
survey were BZP, GBL, synthetic cannabinoids, khat and salvia divinorum.  For the 
same period, 0.4 per cent of respondents reported taking mephedrone, and 0.2 per 
cent had taken ketamine.  This compares to 5.1 per cent for cannabis (the most 
reported drug used), 1.7 per cent for cocaine, and 1.3 per cent for ecstasy.  The 
SCJS found NPS-use to be more prevalent in the 16-24 age group than those aged 
25-44.29   
 
The Scottish Schools Adolescent Lifestyle and Substance Use Survey 2013 
(SALSUS)30 also reported low rates of NPS-use.  For example, four per cent of 15 
year olds reported ever using one or more new psychoactive substances (including 
GBL/GHB, mephedrone, salvia, synthetic cannabis and powers or pills that are sold 
as legal highs). Of these, 2 per cent reported having taken at least one NPS in the last 
month.  By contrast, 9 per cent of the same cohort reported cannabis use in the past 
month.  Therefore, while NPS now constitute an important part of the Scottish drug 
economy, the SCJS and SALSUS suggest prevalence of use is low, both in the 
general population and in comparison to other drugs. 
 
There are, though, limitations to this data.  First, marginal groups are likely to be 
missed in these general surveys.  The SCJS is a survey of private households, while 
SALSUS targets school pupils.  Those with chaotic drug use and/or precarious living 
arrangements, for example, are under-represented. Furthermore, when drug use is 
focused in a particular subpopulation, such surveys will under-report use.  This may 
well be the case with NPS, e.g. concentrated prevalence in club drug and opiate 
users.  Second, not all NPS are included in these surveys.  Supply and demand for 
NPS fluctuate, which means new substances rapidly appear, before fading quickly 
from the market.  Surveys, such as the SCJS and SALSUS struggle to keep-up with 
this rate of change.  This is compounded by problems in establishing the chemical 
contents of NPS products.  NPS-users are often unable to accurately state what they 
have consumed, due to a lack of product information and inconsistencies between 
packages.31   
 
Targeted online surveys may provide valuable information on prevalence of NPS-use 
within certain subgroups of the population, but they too face similar problems to 
                                            
28
 Robertson, Laura, with Bates, Ellie, (2014), The Scottish Crime and Justice Survey Drug Use, 
Scottish Centre for Crime and Justice Research: University of Glasgow, Scottish Government Social 
Research 
29
 Ibid. 
30
NHS National Services Scotland (2014) Scottish Schools Adolescent Lifestyle 
and Substance Use Survey (SALSUS) Drug Use Report . 
31
 For more discussion of the challenges of gathering data on NPS, see Gillies, Allan, (2014), 
Mapping Current and Potential Sources of Routine Data Capture on NPS in Scotland, Scottish 
Government document. 
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those described previously.  For example, the 2014 GDS demonstrates that 
prevalence of NPS-use in clubbers is substantially higher than the general 
population. In UK-wide data, 12 per cent of respondents reported using legal highs, 
research chemicals and/or synthetic cannabis in the 12 months prior to the survey 
(conducted during November / December 2013)32. The online survey My Legal High 
is aimed more widely, seeking information from young people and adults throughout 
the UK.33  As in the previous cases, though, marginal groups are likely to be missed, 
while a reliance on self-reporting reduces reliability.  Therefore, although survey data 
has a role to play, a variety of sources are needed to strengthen the evidence base 
on NPS prevalence in Scotland. 
 
Existing and potential systems of data capture on NPS 
 
Stakeholder organisations may be able to support this process through their systems 
of data capture.  Existing sources may be exploited to outline prevalence of NPS-use 
in Scotland, at a general level and within specific subgroups.34  For example, records 
of telephone and online enquiries to the National Poisons Information Service (NPIS) 
provide an indicator of trends in NPS-use.35  Currently, this data is collected at a UK-
level, but it may be disaggregated to give Scotland-specific analysis.  Additionally, 
the Scottish Drug Misuse Database (SDMD) collects data on individuals presenting 
to drug treatment services, including those reporting NPS-use.  At this stage, though, 
data on NPS-users in the SDMD is relatively sparse; constituting a small percentage 
of the total number of people presenting to drug treatment services in Scotland.  
Further to this, efforts to incorporate NPS into the national system for recording 
transactions in needle exchanges (NEO) for 2013/14 may give an insight into the 
scale of NPS-use in injecting drug users. 
 
There are also a number of potential sources of data capture on NPS in Scotland, 
which currently do not include NPS in their reporting systems.  Within NHS Scotland, 
for example, patient recording systems do not have coding for NPS.  This means 
that information is being lost on patients presenting due to NPS-use.  A & E, in 
particular, is potentially a valuable source of data capture on NPS, picking-up on 
prevalence and harms in a range of populations.   
 
Although there is scope to improve this, it is important to first clearly define the key 
research questions on NPS prevalence in Scotland and how best to address them.  
Mining information on NPS from across the Health Service and other sectors may be 
an ineffective use of resources.  Due to the fast-moving nature of the NPS market, 
information gleaned from these data systems may quickly become outdated.  
Bespoke research may, then, offer a more efficient and timely alternative for 
addressing certain research questions.  
 
 
 
 
                                            
32
 Winstock, A (2014) The Global Drug Survey 2014 Findings, accessed 3.2.2015  
33
 Yet to publish full results, although a summary of the key findings is available at: 
http://www.drugmisuseresearch.org/ 
34
 These are described in greater detail in Gillies, (2014). 
35
 NPIS, (2014), National Poisons Information Service Report 2013/14, , p.36. 
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Investigating NPS-prevalence in subpopulations 
 
Stakeholders have expressed their concerns over NPS-use in marginal subgroups of 
the population.  Anecdotal reports suggest that NPS-use is on the increase among 
long-term drugs users, young people in care, those with mental health issues and 
prisoners.  The consequences of NPS-use in these vulnerable groups may be more 
severe, especially where NPS are taken with other drugs (polydrug use).  Frontline 
staff are already witnessing extreme adverse reactions to NPS in these subgroups, 
e.g. psychosis.  Operating with incomplete information, staff are often unsure of how 
best to respond.  There are also reports indicating differentiation between areas, e.g. 
NPS-use among injecting drug users is believed to be especially pronounced in 
Edinburgh.  These trends may be temporary: ‘drug fads’ which die out.  However, 
there are fears that the problem could escalate.   
 
Bespoke research projects, focusing on these subgroups, may strengthen the 
evidence base on NPS.  By establishing prevalence within vulnerable 
subpopulations where NPS-use may be more concentrated, such research may 
supplement the high-level data collected by general population surveys.  Outlining 
the scale of the problem within these ‘at-risk’ groups is critical to prioritising 
resources and developing guidelines around treatment, prevention and harm 
reduction. 
 
 
Proposals 
Exploit existing sources to outline NPS prevalence in Scotland, including the SCJS, 
SALSUS, My Legal High and records of enquiries to the NPIS. 
 
Work with stakeholder organisations to support integration of NPS into standard 
reporting procedures where appropriate, thereby enhancing data capture of NPS-
use. 
 
Consider bespoke research into the prevalence of NPS-use in vulnerable subgroups 
of the general population.  This may also include geospatial mapping of the problem. 
 
The associated harms of NPS-use 
 
Stakeholders identified the harms associated with NPS-use as one of the most 
pressing evidence gaps on the issue.  There is generally a lack of comprehensive 
information on the acute and long-term harms of such substances.  As the market 
evolves, new forms of NPS emerge.  Gathering accurate and up-to-date information 
on their effects, then, poses difficulties.  This is compounded by the following 
problems: 
 
 Matching specific chemical compound(s) present in NPS products to harms:  
There are hundreds of NPS products, sold under different brand names.  
Packages contain different mixtures and ratios of chemical compounds.  Even 
for products with the same brand name, chemical compositions are 
inconsistent.  Furthermore, individuals buying substances from street-level 
dealers may be unaware of the contents.  NPS users, then, are often unable 
to state accurately what they have consumed.    
 12 
 
 
 Routine blood and urine screens do not pick-up on NPS:  Although there are 
new rapid detection methods to identify these substances, access, at this 
time, is limited.  Incomplete information on how long different NPS stay in the 
body, how they synthesise with different substances, and difficulties in testing 
for miniscule quantities add to the problem. 
 
 Integrating NPS into formal data capture systems:  As noted in the previous 
section, incomplete recording systems mean that evidence related to patients 
presenting with reported NPS-use is currently limited.  Again, there may be 
scope to enhance systems of data capture in some sectors to pick-up on 
these harms. 
 
Sources on NPS-harms in Scotland 
 
There are efforts to improve knowledge of the harms caused by NPS-use in 
Scotland.   
 
Information on deaths related to NPS is captured in reports from National Records of 
Scotland (NRS), and as part of the National Drug Related Death Database 
(NDRDD), which has been managed by  NHS Scotland – Information Services 
Division (ISD) since 200936. The most recent NRS annual report on drug related 
deaths shows that NPS have been implicated in a number of deaths from 2009 
onwards (when the first Scottish deaths involving NPS were registered37).  Deaths 
where NPS were found to be present in the body have increased over this period, 
from 4 in 2009, 47 in 2012, to 113 in 201338.  Deaths where it was reported that one 
(or more) NPS were implicated in, or potentially contributed to, the death were lower, 
but again have increased, from 3 in 2009 to 60 in 201339. However, in only 5 of the 
60 cases reported in 2013 were NPS the only substances implicated in the death40.   
 
In addition to these figures, the most recent NDRDD report was published in 2014, 
(based on deaths recorded in 2012)41. This analysed a subset of drug-related deaths 
involving NPS, providing more detail on the characteristics of 36 individuals and the 
circumstances surrounding their death. This showed that the majority of deaths were 
amongst males (29 deaths) and that two distinct groups of drugs were present in 
NPS related deaths - ‘benzodiazepine’ type drugs, mainly phenazepam, and 
‘stimulant’ type drugs. Polydrug use was a key feature of the NPS related drugs 
related deaths.42  
 
The NPIS draws on medical and scientific evidence, as well as analysis from the 
EMCDDA, to provide information on NPS-toxicity to healthcare professionals.  As 
                                            
36
 NHS National Services Scotland – ISD Scotland (2014) The National Drug-Related Deaths 
Database (Scotland) Report: Analysis of Deaths occurring in 2012 
37
 National Records of Scotland (2014) Drug-related deaths in Scotland in 2013 
38
 Ibid 
39
 Ibid 
40
 Ibid 
41
 NHS National Services Scotland – ISD Scotland (2014) The National Drug-Related Deaths 
Database (Scotland) Report: Analysis of Deaths occurring in 2012 
42
 Ibid 
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part of this, information is gathered on patients and their symptoms during phone 
enquiries to the NPIS43.  This UK-level data may also be disaggregated, giving 
Scotland-specific analysis on the associated harms of NPS-use.  There are also 
moves to supplement NPIS clinical data with routine analysis of blood samples.44  
Collaboration between NPIS and NHS Lothian, for example, used laboratory based 
follow up to confirm clinical diagnoses from poisoned patients who reported taking 
‘Ivory Wave’.45 
 
Those providing frontline services are also gathering information on various aspects 
of NPS.  This includes third-sector organisations and local practitioners, such as 
healthcare professionals and service providers.  Although evidence collected at this 
level is largely anecdotal, such groups are sensitive to the changing dynamics of 
NPS-use on the ground.  The focus tends to be on formulating practical guidelines 
for responding to NPS, such as advancing harm reduction messages.  For example, 
local practitioners in Edinburgh have recently formed an NPS group, to discuss and 
share their experiences of NPS-use.  This included representatives from the 
Forensic Medical Examiner Service, community based addiction specialists, acute 
health wards, psychiatric services, A & E and toxicology.   Immediate plans are to 
introduce interim protocols for treatment, and pathway for sharing information. 
 
In addition to this, the Scottish Government-funded, ‘Recreational Drug Intoxication 
Project: Detecting Novel Psychoactive Substances’ will screen blood and urine 
samples in those presenting with recreational drug intoxication/complications at A & 
E in the Glasgow Royal Infirmary.  The project is a collaboration between NHS 
Greater Glasgow and Clyde, and the University of Glasgow Toxicology Department.  
In such cases currently, the implicated-NPS is rarely identified; in others, it will only 
be detected at autopsy.  The project aims to address this, aiding the process of 
matching harms to specific NPS.   
 
Exploiting UK-wide and European sources 
 
Information gathered at a UK-wide and European level is also crucial in closing this 
evidence gap.  Although there are unique dynamics to the issue in Scotland, the 
harms caused by specific forms of NPS are common across borders.  Initiatives, 
such as the Welsh Emerging Drugs and Identification of Novel Substances Project 
(WEDINOS), then, should be utilised.  WEDINOS analyses samples of NPS 
provided by individuals and partner organisation.  This resource can offer information 
on the chemical compounds present in NPS products, as well as trends and harms 
associated with their use.   
 
There are numerous EU-funded projects exploring the harms associated with NPS.46  
The Euro-DEN project, for example, was established in recognition of the important 
                                            
43
 NPIS (2014) National Poisons Information Service Report 2013/14  
44
 To implement in all cases, this would require additional resources. 
45
 Desoxypipradol was the active ingredient identified in samples of 'Ivory Wave' powder and 
biological fluids.  For more information see Murray, et al, (2012), ‘'Ivory wave' toxicity in recreational 
drug users; integration of clinical and poisons information services to manage legal high poisoning’, 
Clinical Toxicology, Vol. 50, No. 2. 
46
 For a complete list and description of these, see: EMCDDA, (2014b) New Psychoactive Substances 
Projects, Studies and Research funded by the European Commission 
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role hospital emergency departments can play in gathering information on the 
frequency of NPS-related presentations and patterns of acute harm associated with 
NPS-use.  As in the case of NHS Scotland, data from hospital coding systems on 
NPS from across Europe is limited.  A network of European emergency departments, 
then, has been created to gather data on these aspects of NPS and strengthen the 
evidence base.47   
 
As well as identifying existing sources on NPS at a national level and dispersing 
these through the network, ‘a minimum dataset collection tool has been developed to 
enable collection of data on individual cases, including basic demographics, self-
reported recreational drugs/NPS used, circumstances of use, clinical features, 
management and outcome’.48  This will be collected over 12 months to geospatially 
map emerging NPS and their pattern of use.  Findings will be reported to the 
EMCDDA EWS and national focal points to inform the risk assessment process for 
NPS.   
 
 
Patterns of NPS-use 
 
Patterns of NPS-use also have important implications for harms.  In terms of NPS-
use in existing drug users, NPS may replace or supplement established drugs.49  
Such users may be part of particular sub-groups of the population, where there are 
commonalities in the types of NPS sought out, how they are used (quantity, in what 
combinations) and method of consumption (see Case Studies Two and Three, page 
15).   
It is also important to explore pathways to NPS-use in first-time drug users; whether 
greater availability of NPS is leading to more people trying drugs, for example.  
Additionally, factors such as demographics (gender, age, income, etc.), geospatial 
trends in drug use (e.g. anecdotal reports suggest injecting NPS is more prevalent in 
Edinburgh than Glasgow), and context of use (setting as well as social context) 
shape patterns of NPS-use.  For example, anecdotal reports suggest a trend, related 
to NPS-use, in weekend ‘house parties’ involving polydrug and alcohol binges over 
several days, without any break in use.  Patterns of use here, and the associated 
harms, are distinct to socially isolated individuals using NPS alone. 
 
Enhancing knowledge on the patterns of NPS-use is critical to formulating an 
effective policy response, as well as guidelines around treatment, education and 
harm reduction.  As patterns of use vary between subgroups, the harms they are 
exposed to also vary. 
 
Again, while survey data can pick-up on these dynamics in some user groups, small-
scale studies of particular subgroups may be needed.  In this way, information may 
be gathered, not only on the direct harms caused by particular NPS and trends in 
dependency, but how these are affected by patterns of use.  This would also be 
valuable in exploring how users understand the harms associated with their NPS-
use. 
                                            
47
 This network does not include any Scottish hospitals. 
48
 Wood, D.M., et. al., (2014), ‘The European Drug Emergencies Network (Euro-Den)’, Clinical 
Toxicology, Early Online 1-3. 
49
 Raising issues around polydrug use in the latter case. 
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Case Study Two: Opiate Users 
 
The 2013 report for drug-related deaths in Scotland identified a trend in Benzo-type 
NPS – e.g. phenazepam and etizolam – being used alongside established drugs, 
such as methadone and heroin.  This is indicative of the ways in which ‘downer’-type 
NPS are being used by opiate users.  Variation in potency between batches of such 
NPS presents significant health risks to individuals using these alongside heroin, for 
example. 
 
Related to this, reports suggest that injecting drug users within this subgroup are 
increasingly turning to NPS.  In Edinburgh, for example, frontline staff have noted 
cases of individuals injecting stimulant-type NPS (cathinones).  Users are believed to 
be drawn, not only by availability and price, but also the intense high of consuming 
these forms of NPS in this way.   
 
Injecting such NPS is corrosive to the skin and veins, and gives a highly potent dose.  
There are also fears that harm reduction measures, based around heroin use, are 
having a limited impact on NPS-injecting behaviour, e.g. individuals experiencing 
drug induced psychosis not following harm reduction advice.  These are magnified 
for first-time drug injectors, who have no connections to heroin injecting circles and 
the ‘folk knowledge’ of this community.  There are major public health risks related to 
this, in terms of the spread of blood borne viruses, for example. 
 
 
Case Study Three: Gay/Men who have Sex with Men Clubbers 
 
NPS are also used by gay/men who have sex with men clubbers, but in different 
ways to the previous case.   
 
Anecdotal reports indicate that NPS are popular in the Glasgow gay/MSM club 
scene.  Although work is needed to outline the patterns of use, there may be 
parallels with similar groups in London.  For example, mephedrone remains popular 
despite control, and is often taken alongside ketamine and GBL.  Furthermore, 
polydrug use with established drugs, such as cocaine and ecstasy, is common.50  In 
these cases, consumption through ingestion or nasal insufflation is more prevalent. 
 
The practice of injecting as part of ‘chem-sex parties’ is believed to be present in this 
subgroup, although there is limited evidence for this in Scotland. ‘Chem-sex parties’ 
involve individuals injecting each other with NPS, typically cathinones, before 
engaging in ‘risky sexual practices’. Health bodies in other parts of the UK have 
expressed concerns that this may increase the spread of blood borne viruses.  For 
example, uncertainty over the contents and strength of NPS, may lead individuals to 
lower inhibitions and place themselves at risk.51 
 
                                            
50
 Home Office, (2014), New Psychoactive Substances Review: Report of the Expert Panel, p.13. 
51
 Wales Online, (2014), ‘Legal high party drugs are leading to increase in sexually transmitted 
diseases, warn experts’, available from http://www.walesonline.co.uk/news, 25 October 2014. 
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Proposal 
 
Where appropriate, support integration of NPS into standard reporting procedures to 
pick-up on the associated harms of use. 
 
Consider bespoke research into the associated harms of NPS-use in vulnerable 
subgroups of the general population.  This could also include patterns of use and 
geospatial mapping of the problem.  
 
 
 
Data sharing between stakeholders 
 
Stakeholders have noted a need for greater collaboration between agencies in 
responding to NPS.  The experiences of NPS of different sectors may be used in 
conjunction to enhance collective knowledge of the issue.   
The issue of NPS has many moving parts, with supply and demand fluctuating.  
From an operational perspective, this poses challenges in gathering and cascading 
accurate information to stakeholder organisations.  Frontline staff may face 
uncertainty when responding to NPS-use due to a lack of information.  
Subsequently, knowledge acquired in such cases may be lost, as gaps remain in 
reporting.   
 
At this time, systems for data sharing are largely informal.  For example, regional 
drug trend monitoring groups meet to discuss the local dynamics of drug 
consumption and supply.  They typically consist of representatives from the Health 
Service, Police Scotland, the local ADP and forensic toxicologists.  Stakeholders are 
able to identify emerging problems and formulate a response.  This has included 
advancing credible health warnings and halting the spread of misinformation.   
 
This model, however, relies on goodwill between agencies, and there is no 
mechanism to disperse this knowledge at a national level, e.g. a Scottish NPS 
database.  Information on the appearance of a new form of NPS in one region may 
be of great value to practitioners facing the issue for the first time in another area.  A 
nation-wide formal system of data collection and sharing could potentially contribute 
to a fuller picture of the prevalence and harms of NPS in Scotland, and the spread of 
timely and accurate information on emerging drug risks.  From an analytical 
perspective, continuous monitoring of the NPS market would help to capture 
changing trends in use, including geospatial mapping of NPS.  The Salford Early-
Warning pilot (Case Study Four) may provide a template for a Scottish model of data 
sharing. 
 
 
Case Study Four: The Salford Early-Warning Pilot 
 
The Salford Early-Warning pilot is designed to enhance scarce existing resources 
and knowledge exchange of practitioners confronting NPS; facilitating the 
identification, risk assessment and response to localised outbreaks of NPS or 
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adulterated drug use.  It has been supported by the third sector organisation, UK 
DrugWatch. 
 
It is a multi-agency system, tailored to the information needs/concerns of 
stakeholders, which enables cascading of information on NPS to frontline staff.  This 
information may also be shared through the media and with other regions and 
national bodies where appropriate. 
 
An online forum is managed by the local Drug and Alcohol Action Team (DAAT, 
equivalent to Scottish ADPs), building on their existing links to local stakeholders, 
e.g. A & E, Police, drug services, etc.  This local professional network allows for the 
rapid sharing of information between organisations, and may be linked into 
regional/national networks in time.  It is a ground-up response to NPS, with an 
operational focus.  However, the information gathered may enhance general 
knowledge on prevalence, harms and trends in NPS-use. 
 
More detailed operational information may be found at:  
http://www.nta.nhs.uk/uploads/salfordewsmodelver10.pdf 
 
Proposal 
 
Consider supporting efforts to set-up formal regional systems of data sharing on 
NPS between stakeholders, linked into a national framework. 
 
 
 
Closing evidence gaps 
 
Progress has been made in strengthening the evidence base for NPS in Scotland.  
There is greater awareness of the issue across sectors and, as stakeholder 
organisations have responded to the emergence of NPS, data has been collected on 
a range of indicators.  This includes, beginning to map out the NPS market, and the 
prevalence, harms, motivations and patterns of use. 
 
Significant gaps, though, remain.  For example, although it may be said that the 
scale of NPS-use in the general population is low, the picture is less clear for certain 
subgroups of the population.  Equally, evidence on the harms of some forms of NPS 
has improved, while knowledge around newer forms of NPS and risks associated 
with particular patterns of use is incomplete.  In closing these gaps, it is critical to 
take into consideration the diversity which exists within the NPS market.  Variation 
along NPS-types, subpopulations, motivations, settings and behaviour must be taken 
into account when engaging with the issue. 
 
The following proposals are set out to aid the process of closing evidence gaps on 
NPS in Scotland.  Several of these represent different dimensions of the same issue; 
for example, understanding prevalence, motivations of use, and the associated 
harms within particular subgroups of the general population.  Taken together, it is 
hoped that these proposals will help to ensure an effective and proportionate 
response to NPS-use in Scotland. 
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Proposals 
 
Defining and categorising NPS 
 
Work with stakeholders to formulate national guidelines for defining and categorising 
NPS.  By establishing standardisation across organisations, the collection and 
sharing of data will be enhanced.  This is crucial to strengthening the evidence base 
on NPS. 
 
The NPS market in Scotland  
 
Support work mapping the market for NPS in Scotland, including how different 
subgroups are accessing NPS.   
 
Explore the possible advantages and disadvantages of introducing ‘pill-testing’ 
facilities in Scotland as a harm-reduction measure. 
 
Motivations for NPS-use 
 
Consider commissioning research into the motivations of NPS-use in key subgroups 
of the population, e.g. high school pupils, college/university students, long-term drug 
users, etc.  
 
Prevalence of NPS-use 
 
Exploit existing sources to outline NPS prevalence in Scotland, including the SCJS, 
SALSUS, My Legal High and records of enquiries to the NPIS. 
 
Work with stakeholder organisations to support integration of NPS into standard 
reporting procedures where appropriate, thereby enhancing data capture of NPS-
use. 
 
Consider research into the prevalence of NPS-use in vulnerable subgroups of the 
general population.  This may also include geospatial mapping of the problem. 
 
 
Harms of NPS-use 
 
Support integration of NPS into standard reporting procedures where appropriate to 
pick-up on the associated harms of use. 
 
Consider research into the associated harms of NPS-use in vulnerable subgroups of 
the general population.  This should also include patterns of use and geospatial 
mapping of the problem. 
 
Data sharing 
 
Consider supporting efforts to set-up formal regional systems of data sharing on 
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NPS between stakeholders, linked into a national framework. 
 
 
  
 20 
 
Bibliography 
 
EMCDDA, (2013), The EU Drug Markets Report: a Strategic Analysis, available from 
http://www.emcdda.europa.eu/attachements.cfm/att_194336_EN_TD3112366ENC.p
df  
 
EMCDDA, (2014a), Perspectives on Drugs: Synthetic Cannabinoids in Europe, 
Available from http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids  
 
EMCDDA, (2014b), New Psychoactive Substances Projects, Studies and Research 
funded by the European Commission, available from: http://ec.europa.eu/justice/anti-
drugs/files/nps_report_2014_en.pdf  
 
EMCDDA-Europol, (2014), EMCDDA-Europol Annual Report on the Implementation 
of Council Decision 2005, available from: 
http://www.emcdda.europa.eu/attachements.cfm/att_229598_EN_TDAN14001ENN.
pdf  
 
Gillies, Allan, (2014), Mapping Current and Potential Sources of Routine Data 
Capture on NPS in Scotland, Scottish Government  
 
Home Office (2014) New Psychoactive Substances Review: Report of the Expert 
Panel, available at: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/36858
3/NPSexpertReviewPanelReport.pdf  
 
Measham, Fiona, (2013), ‘Social Issues in the Use of Novel Psychoactive 
Substances: Differentiated Demand and Ideological Supply’, in Dargan & Wood, 
(Eds.), Novel Psychoactive Substances: Classification, Pharmacology and 
Toxicology, London: Academic Press. 
 
Mixmag, (2012), Mixmag’s Drug Survey: The Results, available from 
http://www.mixmag.net/drugssurvey 14 March 2012 
 
Mixmag (2013) Mixmag’s Global Drug Survey: The Results, accessed 3.2.2015 
 
Murray, et al, (2012), ‘'Ivory wave' toxicity in recreational drug users; integration of 
clinical and poisons information services to manage legal high poisoning’, Clinical 
Toxicology, Vol. 50, No. 2. 
 
National Records of Scotland, (2014) Drug-Related Deaths in Scotland in 2013. 
http://www.gro-scotland.gov.uk/statistics/theme/vital-events/deaths/drug-
related/2012/index.html 
 
NHS National Services Scotland – ISD Scotland (2014) The National Drug-Related 
Deaths Database (Scotland) Report: Analysis of Deaths occurring in 2012, available 
at: https://isdscotland.scot.nhs.uk/Health-Topics/Drugs-and-Alcohol-
Misuse/Publications/2014-03-25/2014-03-25-NDRDD-Report.pdf?10337466002  
 
 
 21 
 
NHS National Services Scotland (2014) Scottish Schools Adolescent Lifestyle and 
Substance Use Survey (SALSUS): Drug Use Report, available at: 
http://www.isdscotland.org/Health-Topics/Public-Health/Publications/2014-11-
25/SALSUS_2013_Drugs_Report.pdf  
 
NPIS, (2014), National Poisons Information Service Report 2013/14, available from: 
http://www.npis.org/NPISAnnualReport2013-14.pdf   
 
Power, Mike, (2013), ‘Killer Pills: Myth or Murder?’, Mixmag, 
http://www.mixmag.net/words/features/killer-pills-myth-or-murder 4 April 2013  
 
Robertson, Laura, with Bates, Ellie (2014) The Scottish Crime and Justice Survey 
Drug Use, Scottish Centre for Crime and Justice Research: University of Glasgow, 
Scottish Government Social Research, available at: 
http://www.gov.scot/Topics/Statistics/Browse/Crime-Justice/crime-and-justice-survey  
 
Scottish Gov., (2014), Drug Seizures by Scottish Police Forces, 2012-13, available 
from http://www.scotland.gov.uk/Publications/2014/03/9481/2  
 
UNODC, (2013), The Challenge of New Psychoactive Substances, a Report from the 
Global SMART Programme, UNODC: Vienna, available at: 
http://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf  
 
Wales Online, (2014), ‘Legal high party drugs are leading to increase in sexually 
transmitted diseases, warn experts’, available from 
http://www.walesonline.co.uk/news/wales-news/legal-high-party-drugs-leading-
7996505 7 November 2014 
 
Winstock, A (2014) The Global Drug Survey 2014 Findings, accessed 3.2.2015 
   
Wood, D.M., et. al., (2014), ‘The European Drug Emergencies Network (Euro-Den)’, 
Clinical Toxicology, Early Online 1-3. 
 
